<VariationArchive VariationID="1074172" VariationName="NM_000049.4(ASPA):c.877_878del (p.Glu293fs)" VariationType="Deletion" Accession="VCV001074172" Version="47" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-29" DateCreated="2021-05-10" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1064140" VariationID="1074172">
      <GeneList>
        <Gene Symbol="SPATA22" FullName="spermatogenesis associated 22" GeneID="84690" HGNC_ID="HGNC:30705" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>17p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="3440019" stop="3513858" display_start="3440019" display_stop="3513858" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="3343304" stop="3375141" display_start="3343304" display_stop="3375141" Strand="-" />
          </Location>
          <OMIM>617673</OMIM>
        </Gene>
        <Gene Symbol="ASPA" FullName="aspartoacylase" GeneID="443" HGNC_ID="HGNC:756" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>17p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="3474110" stop="3503405" display_start="3474110" display_stop="3503405" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="3377403" stop="3402699" display_start="3377403" display_stop="3402699" Strand="+" />
          </Location>
          <OMIM>608034</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000049.4(ASPA):c.877_878del (p.Glu293fs)</Name>
      <CanonicalSPDI>NC_000017.11:3499021:AGA:A</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="3499022" stop="3499023" display_start="3499022" display_stop="3499023" variantLength="2" positionVCF="3499021" referenceAlleleVCF="AAG" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="3402316" stop="3402317" display_start="3402316" display_stop="3402317" variantLength="2" positionVCF="3402315" referenceAlleleVCF="AAG" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>E293fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.3402317_3402318del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.3402317_3402318del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.3499023_3499024del" Assembly="GRCh38">
            <Expression>NC_000017.11:g.3499023_3499024del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008399.3" sequenceAccession="NG_008399" sequenceVersion="3" change="g.29915_29916del">
            <Expression>NG_008399.3:g.29915_29916del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000049.4" sequenceAccession="NM_000049" sequenceVersion="4" change="c.877_878del" MANESelect="true">
            <Expression>NM_000049.4:c.877_878del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000040.1" sequenceAccession="NP_000040" sequenceVersion="1" change="p.Glu293fs">
            <Expression>NP_000040.1:p.Glu293fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001128085.1" sequenceAccession="NM_001128085" sequenceVersion="1" change="c.877_878del">
            <Expression>NM_001128085.1:c.877_878del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001121557.1" sequenceAccession="NP_001121557" sequenceVersion="1" change="p.Glu293fs">
            <Expression>NP_001121557.1:p.Glu293fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001321336.2" sequenceAccession="NM_001321336" sequenceVersion="2" change="c.-74+14389_-74+14390del">
            <Expression>NM_001321336.2:c.-74+14389_-74+14390del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001321337.2" sequenceAccession="NM_001321337" sequenceVersion="2" change="c.-74+14389_-74+14390del">
            <Expression>NM_001321337.2:c.-74+14389_-74+14390del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2150764223" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000049.4(ASPA):c.877_878del (p.Glu293fs) AND Spongy degeneration of central nervous system" Accession="RCV001387392" Version="17">
        <ClassifiedConditionList TraitSetID="670">
          <ClassifiedCondition DB="MedGen" ID="C0206307">Spongy degeneration of central nervous system</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-02-26" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-02-26" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-05-10" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10909858</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16217711</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22850825</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8023850</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8659549</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="670" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="651" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Spongy degeneration of central nervous system</ElementValue>
                <XRef ID="Canavan+Disease/1042" DB="Genetic Alliance" />
                <XRef ID="80544005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Canavan-van Bogaert-Bertrand disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Spongy degeneration of the central nervous system</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Von Bogaert-Bertrand disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Aspartoacylase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ASP deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ACY2 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Aminoacylase 2 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Canavan disease</ElementValue>
                <XRef ID="MONDO:0010079" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5984" />
                <XRef ID="5984" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Most individuals with Canavan disease have the neonatal/infantile form. Although such infants appear normal early in life, by age three to five months, hypotonia, head lag, macrocephaly, and developmental delays become apparent. With age, children with neonatal/infantile-onset Canavan disease often become irritable and experience sleep disturbance, seizures, and feeding difficulties. Swallowing deteriorates, and some children require nasogastric feeding or permanent feeding gastrostomies. Joint stiffness increases, so that these children resemble individuals with cerebral palsy. Children with mild/juvenile Canavan disease may have normal or mildly delayed speech or motor development early in life without regression. In spite of developmental delay most of these children can be educated in typical classroom settings and may benefit from speech therapy or tutoring as needed. Most children with mild forms of Canavan disease have normal head size, although macrocephaly, retinitis pigmentosa, and seizures have been reported in a few individuals.</Attribute>
                <XRef ID="NBK1234" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301412</ID>
                <ID Source="BookShelf">NBK1234</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2011">
                <URL>http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Carrier-Screening-ACT-SheetAshkenazi-Jewish-Genetic-Disorders.aspx</URL>
                <CitationText>American College of Medical Genetics ACT Sheet, Carrier Screening ACT Sheet Ashkenazi Jewish Genetic Disorders</CitationText>
              </Citation>
              <XRef ID="141" DB="Orphanet" />
              <XRef ID="C0206307" DB="MedGen" />
              <XRef ID="MONDO:0010079" DB="MONDO" />
              <XRef Type="MIM" ID="271900" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3113667" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="9993659|MedGen:C0206307" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001588008" DateUpdated="2024-02-20" DateCreated="2021-05-10" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-02-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8659549</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8023850</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22850825</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10909858</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16217711</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the ASPA protein. Other variant(s) that disrupt this region (p.Glu293Leufs*8, p.Ala305Glu) have been determined to be pathogenic (PMID: 8659549, 8023850, 22850825, 10909858, 16217711). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has not been reported in the literature in individuals with ASPA-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change results in a premature translational stop signal in the ASPA gene (p.Glu293Serfs*7). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 21 amino acids of the ASPA protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ASPA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.3402316_3402317del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0206307" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3113667" TraitType="Disease" MappingType="XRef" MappingValue="C0206307" MappingRef="MedGen">
        <MedGen CUI="C0206307" Name="Spongy degeneration of central nervous system" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

